EGFR and non-small cell lung carcinoma: Finally, the FLAURA trial demonstrated the superior efficacy and safety of osimertinib compared with gefitinib and erlotinib as first-line TKIs in EGFR mutant NSCLC patients, and osimertinib is therefore currently considered the standard for first-line therapy (46).